Literature DB >> 22269108

Regulation of TGF-β1 expression by androgen deprivation therapy of prostate cancer.

Paolo Fuzio1, Pasquale Ditonno, Monica Rutigliano, Michele Battaglia, Carlo Bettocchi, Antonia Loverre, Giuseppe Grandaliano, Elda Perlino.   

Abstract

In this paper we studied the in vivo neoadjuvant Androgen Deprivation Therapy (ADT) effect on the expression of TGF-β1 and its receptor Tβ-RII. Mechanisms of androgen dependence are critical to understanding prostate cancer progression to androgen independence associated with disease mortality, and TGF-β is thought to support prostatic apoptosis as its expression coincides with androgen ablation in benign and cancer tissues. Increase of both mRNA and protein level were shown for the first time only in the patients who underwent neoadjuvant ADT for 1-month. This transient increase of TGF-β expression after androgen ablation suggested cooperation of the pathways in prostate regression. Since no alteration was observed in the gene transcriptional activity, the molecular mechanism of this cooperation, probably act at the post-transcriptional level. TGF-β1 and Tβ-RII specific signals were co-localized within the neoplastic prostate epithelium. Our results suggests that the androgens deprivation by means of ADT for 1-month, involves a shift of the TGF-β1 mechanism in prostate cancer, suggesting that the TGF-β1 promotes prostate epithelial cell proliferation and inhibits apoptosis in a autocrine way. Copyright Â
© 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22269108     DOI: 10.1016/j.canlet.2011.08.034

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  8 in total

Review 1.  Restoring TGFβ1 pathway-related microRNAs: possible impact in metastatic prostate cancer development.

Authors:  Juliana Inês Santos; Ana Luísa Teixeira; Francisca Dias; Mónica Gomes; Augusto Nogueira; Joana Assis; Rui Medeiros
Journal:  Tumour Biol       Date:  2014-04-25

Review 2.  The Role of Testosterone in the Treatment of Castration-Resistant Prostate Cancer.

Authors:  Michael W Drazer; Walter M Stadler
Journal:  Cancer J       Date:  2016 Sep/Oct       Impact factor: 3.360

3.  TGF-β1 signaling pathway serves a role in HepG2 cell regulation by affecting the protein expression of PCNA, gankyrin, p115, XIAP and survivin.

Authors:  Xin-Hong Wang; Zhi-Guo Chen; Rui-Ling Xu; Cheng-Qian Lv; Jing Liu; Bing Du
Journal:  Oncol Lett       Date:  2017-03-06       Impact factor: 2.967

Review 4.  Autophagy in prostate cancer and androgen suppression therapy.

Authors:  Elio Ziparo; Simonetta Petrungaro; Elettra Sara Marini; Donatella Starace; Silvia Conti; Antonio Facchiano; Antonio Filippini; Claudia Giampietri
Journal:  Int J Mol Sci       Date:  2013-06-06       Impact factor: 5.923

5.  Inhibitory effect of curcumin on testosterone induced benign prostatic hyperplasia rat model.

Authors:  Su Kang Kim; Hosik Seok; Hae Jeong Park; Hye Sook Jeon; Sang Wook Kang; Byung-Cheol Lee; Jooil Yi; Sang Yeol Song; Sang Hyub Lee; Young Ock Kim; Joo-Ho Chung
Journal:  BMC Complement Altern Med       Date:  2015-10-22       Impact factor: 3.659

Review 6.  TGF-β cascade regulation by PPP1 and its interactors -impact on prostate cancer development and therapy.

Authors:  Luís Korrodi-Gregório; Joana Vieira Silva; Luís Santos-Sousa; Maria João Freitas; Juliana Felgueiras; Margarida Fardilha
Journal:  J Cell Mol Med       Date:  2014-03-15       Impact factor: 5.310

7.  A switch from CD44⁺ cell to EMT cell drives the metastasis of prostate cancer.

Authors:  Zhiqun Shang; Qiliang Cai; Minghao Zhang; Shimiao Zhu; Yuan Ma; Libin Sun; Ning Jiang; Jing Tian; Xiaodan Niu; Jiatong Chen; Yinghao Sun; Yuanjie Niu
Journal:  Oncotarget       Date:  2015-01-20

8.  A Conformational Change in C-Reactive Protein Enhances Leukocyte Recruitment and Reactive Oxygen Species Generation in Ischemia/Reperfusion Injury.

Authors:  Jan R Thiele; Johannes Zeller; Jurij Kiefer; David Braig; Sheena Kreuzaler; Yvonne Lenz; Lawrence A Potempa; Florian Grahammer; Tobias B Huber; M Huber-Lang; Holger Bannasch; G Björn Stark; Karlheinz Peter; Steffen U Eisenhardt
Journal:  Front Immunol       Date:  2018-04-16       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.